Table 3.
Prenatal exposure to acid suppressant medications and the development of asthma: meta-analysis results
| Author (year) |
# of Studies Included |
Author (year) of studied included | Publication bias (P value for Egger test) |
Asthma* | ||
|---|---|---|---|---|---|---|
| Prenatal Exposure | Result | Heterogeneity | ||||
| Devine (2017) [35] | 8 | Dehlink (2009), Kallen (2013), Hak (2013), Mulder (2013), Mulder (2014), Andersen (2012), Cea Soriano (2016), Yitshak-Sade (2016) | Unlikely (P=0.415) | Any ASM H2RA PPI |
RR 1.36 (1.16 −1.61) RR 1.46 (1.29-1.65) RR 1.30 (1.07-1.56) |
I2 = 87.6% I2= 15.3% I2= 42.5% |
| Lai (2018) [36] | 8 | Dehlink (2009), Kallen (2013), Hak (2013), Mulder (2013), Mulder (2014, Andersen (2012), Cea Soriano (2016), Yitshak-Sade (2016) | Unlikely (P>0.05) | Any ASM H2RA PPI |
RR 1.31 (1.15-1.49) RR 1.57 (1.46-1.69) RR 1.34 (1.18-1.52) |
I2 = 84% I2= 0% I2= 46% |
| 5 | Dehlink (2009), Kallen (2013), Mulder (2013), Mulder (2014), Andersen (2012), Cea Soriano (2016) | Unlikely (P>0.05) | Any ASM** | RR 1.45 (1.35-1.56) | I2 = 0% | |
Abbreviations: ASM: acid suppressant medications, BMI: body mass index, GRADE: Grading of Recommendations, Assessment, Development and Evaluation, H2RA: histamine-2 receptor antagonist, PPI: proton pump inhibitor, NOS: Newcastle-Ottowa Sclae.
*
Other allergic diseases included atopic dermatitis, food allergy, allergic rhinitis, eosinophilic esophagitis, drug hypersensitivity reaction or other allergic reactions. However, there was insufficient data for analysis of these outcomes.
**
Results of sensitivity analysis.